Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection

Disha Bhavsar; Gagandeep Singh; Kaori Sano; Charles Gleason; Komal Srivastava; PARIS Study Group; Juan Manuel Carreno; Viviana Simon; Florian Krammer

doi:10.1128/mbio.02280-23

Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection

mBio. 2023 Dec 1;14(6):e0228023. doi: 10.1128/mbio.02280-23. Online ahead of print.

Authors

Disha Bhavsar^#^{1

2}, Gagandeep Singh^#^{1

2}, Kaori Sano^#^{1

2}, Charles Gleason^{1

2}, Komal Srivastava^{1

2}; PARIS Study Group^{1

2}; Juan Manuel Carreno^{1

2}, Viviana Simon^{1

2

3

4

5}, Florian Krammer^{1

2

3}

Collaborators

Affiliations

¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁵ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

^# Contributed equally.

Abstract

Antibodies on mucosal surfaces of the upper respiratory tract have been shown to be important for protection from infection with SARS-CoV-2. Here we investigate the induction of serum IgG, saliva IgG, and saliva sIgA after COVID-19 mRNA booster vaccination or breakthrough infections.

Keywords: SARS-CoV-2; booster vaccination; breakthrough infection; mRNA vaccine; sIgA; saliva; spike.

Abstract

Grants and funding